(VIANEWS) – Zillow Group (ZG), KKR & Co. (KKR), Corcept Therapeutics Incorporated (CORT) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Zillow Group (ZG)

158.2% sales growth and 3.05% return on equity

Zillow Group, Inc. operates real estate brands on mobile and the web in the United States.

Zillow Group’s sales growth this year is expected to be 96.9% and 48.3% for next year.

Year-on-year quarterly revenue growth grew by 70.5%, now sitting on 3.97B for the twelve trailing months.

Volume

Today’s last reported volume for Zillow Group is 387200 which is 29.98% below its average volume of 553035.

Zillow Group’s sales growth for the next quarter is 158.2%. The company’s growth estimates for the current quarter and the next is a negative 56.8% and negative -65.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.05%.

Volatility

Zillow Group’s last day, last week, and last month’s current volatility was 1.60%, 1.59%, and 1.78%, respectively.

Zillow Group’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.63% (day), 2.76% (last week), and 3.42% (last month), respectively.

Zillow Group’s Stock Yearly Top and Bottom Value

Zillow Group’s stock is valued at $92.12 at 01:22 EST, way below its 52-week high of $212.40 and higher than its 52-week low of $86.11.

Zillow Group’s Moving Average

Zillow Group’s worth is below its 50-day moving average of $100.04 and way under its 200-day moving average of $119.67.

Previous days news about Zillow Group(ZG)

  • According to Benzinga on Tuesday, 14 September, "The COVID-19 pandemic era’s shift to remote work will continue to shape the housing market after the health crisis has faded, according to a new survey from Zillow Group Inc. (NASDAQ: Z)."

2. KKR & Co. (KKR)

44.5% sales growth and 38.03% return on equity

KKR & Co.’s sales growth this year is expected to be 48.9% and 14.1% for next year.

Year-on-year quarterly revenue growth grew by 126%, now sitting on 24.31B for the twelve trailing months.

Volume

Today’s last reported volume for KKR & Co. is 5063160 which is 112.91% above its average volume of 2378020.

KKR & Co.’s sales growth for the next quarter is 44.5%. The company’s growth estimates for the current quarter and the next is 85.4% and 89.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 38.03%.

Volatility

KKR & Co.’s last day, last week, and last month’s current volatility was 0.02%, 0.14%, and 0.75%, respectively.

KKR & Co.’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.69% (day), 1.53% (last week), and 1.58% (last month), respectively.

KKR & Co.’s Stock Yearly Top and Bottom Value

KKR & Co.’s stock is valued at $64.62 at 01:22 EST, under its 52-week high of $67.81 and way higher than its 52-week low of $32.73.

KKR & Co.’s Moving Average

KKR & Co.’s worth is higher than its 50-day moving average of $64.34 and way higher than its 200-day moving average of $56.97.

3. Corcept Therapeutics Incorporated (CORT)

21.3% sales growth and 19.99% return on equity

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States.

Corcept Therapeutics Incorporated’s sales growth this year is anticipated to be 5.3% and 14.7% for next year.

Year-on-year quarterly revenue growth grew by 3.4%, now sitting on 343.09M for the twelve trailing months.

Volume

Today’s last reported volume for Corcept Therapeutics Incorporated is 230584 which is 56.33% below its average volume of 528070.

Corcept Therapeutics Incorporated’s sales growth is a negative 0% for the ongoing quarter and 21.3% for the next. The company’s growth estimates for the current quarter and the next is 17.6% and 10%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.99%.

Volatility

Corcept Therapeutics Incorporated’s last day, last week, and last month’s current volatility was 0.80%, 0.98%, and 0.99%, respectively.

Corcept Therapeutics Incorporated’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.18% (day), 1.58% (last week), and 2.18% (last month), respectively.

Corcept Therapeutics Incorporated’s Stock Yearly Top and Bottom Value

Corcept Therapeutics Incorporated’s stock is valued at $20.60 at 01:22 EST, way under its 52-week high of $31.18 and way higher than its 52-week low of $16.42.

Corcept Therapeutics Incorporated’s Moving Average

Corcept Therapeutics Incorporated’s worth is under its 50-day moving average of $21.01 and under its 200-day moving average of $22.26.

4. Sapiens International Corporation N.V. (SPNS)

17.8% sales growth and 12.36% return on equity

Sapiens International Corporation N.V. provides software solutions for the insurance and financial services industries in North America, Europe, the Asia Pacific, and South Africa.

Sapiens International Corporation N.V.’s sales growth this year is anticipated to be 20.8% and 9.7% for next year.

Year-on-year quarterly revenue growth grew by 22.9%, now sitting on 423.3M for the twelve trailing months.

Volume

Today’s last reported volume for Sapiens International Corporation N.V. is 58033 which is 49.4% below its average volume of 114695.

Sapiens International Corporation N.V.’s sales growth for the next quarter is 17.8%. The company’s growth estimates for the present quarter and the next is 7.4% and 11.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.36%.

Volatility

Sapiens International Corporation N.V.’s last day, last week, and last month’s current volatility was 0.59%, 0.87%, and 0.95%, respectively.

Sapiens International Corporation N.V.’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.56% (day), 1.85% (last week), and 1.80% (last month), respectively.

Sapiens International Corporation N.V.’s Stock Yearly Top and Bottom Value

Sapiens International Corporation N.V.’s stock is valued at $28.24 at 01:22 EST, way under its 52-week high of $35.85 and way above its 52-week low of $24.30.

Sapiens International Corporation N.V.’s Moving Average

Sapiens International Corporation N.V.’s value is above its 50-day moving average of $27.65 and below its 200-day moving average of $28.98.

5. Good Life Advisors, LLC (ABB)

9.8% sales growth and 7.18% return on equity

Good Life Advisors, LLC’s sales growth this year is expected to be 13.5% and 5.5% for next year.

Year-on-year quarterly revenue growth grew by 21%, now sitting on 28.11B for the twelve trailing months.

Volume

Today’s last reported volume for Good Life Advisors, LLC is 973983 which is 20.78% below its average volume of 1229590.

Good Life Advisors, LLC’s sales growth for the next quarter is 9.8%. The company’s growth estimates for the current quarter and the next is 90.5% and 57.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.18%.

Volatility

Good Life Advisors, LLC’s last day, last week, and last month’s current volatility was 0.43%, 0.72%, and 0.66%, respectively.

Good Life Advisors, LLC’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.10% (day), 0.91% (last week), and 0.82% (last month), respectively.

Good Life Advisors, LLC’s Stock Yearly Top and Bottom Value

Good Life Advisors, LLC’s stock is valued at $36.63 at 01:22 EST, below its 52-week high of $38.03 and way above its 52-week low of $24.07.

Good Life Advisors, LLC’s Moving Average

Good Life Advisors, LLC’s value is under its 50-day moving average of $37.20 and above its 200-day moving average of $34.15.

6. Canadian Pacific Railway (CP)

9.8% sales growth and 35.58% return on equity

Canadian Pacific Railway Limited, together with its subsidiaries, owns and operates a transcontinental freight railway in Canada and the United States.

Canadian Pacific Railway’s sales growth this year is anticipated to be 7.7% and 7.3% for next year.

Year-on-year quarterly revenue growth declined by 4.1%, now sitting on 7.63B for the twelve trailing months.

Volume

Today’s last reported volume for Canadian Pacific Railway is 14078200 which is 299.36% above its average volume of 3525180.

Canadian Pacific Railway’s sales growth is a negative 0% for the ongoing quarter and 9.8% for the next. The company’s growth estimates for the present quarter and the next is 27.7% and 11.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.58%.

Volatility

Canadian Pacific Railway’s last day, last week, and last month’s current volatility was 2.67%, 3.10%, and 1.27%, respectively.

Canadian Pacific Railway’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.61% (day), 4.28% (last week), and 2.11% (last month), respectively.

Canadian Pacific Railway’s Stock Yearly Top and Bottom Value

Canadian Pacific Railway’s stock is valued at $68.81 at 01:22 EST, way below its 52-week high of $83.07 and way higher than its 52-week low of $58.17.

Canadian Pacific Railway’s Moving Average

Canadian Pacific Railway’s worth is below its 50-day moving average of $71.79 and under its 200-day moving average of $74.92.

Previous days news about Canadian Pacific Railway(CP)

  • According to Business Insider on Wednesday, 15 September, "Kansas City Southern (KSU) announced Wednesday that its Board of Directors, in consultation with its financial and legal advisors, has unanimously determined that the acquisition proposal KCS received from Canadian Pacific Railway Limited (CP, CP.TO) on September 12, 2021 continues to constitute a "Company Superior Proposal" under KCS’s pending merger agreement with Canadian National Railway Company (CNR.TO, CNI)."
  • According to Bloomberg Quint on Wednesday, 15 September, "When a rival threatened to steal Canadian Pacific Railway Ltd.’s dream acquisition, Chief Executive Officer Keith Creel bet his company’s future on a hunch supported by his younger days operating trains across the central U.S."
  • According to The Wall Street Journal on Sunday, 12 September, "Kansas City Southern said a recent takeover offer from Canadian Pacific Railway Ltd. "
  • According to Bloomberg Quint on Wednesday, 15 September, "Canadian National Railway Co. has declined to increase its offer for Kansas City Southern after a months-long takeover battle, a person familiar with the matter said, ceding to Canadian Pacific Railway Ltd. "

7. Genpact Limited (G)

9.8% sales growth and 20.25% return on equity

Genpact Limited provides business process outsourcing and information technology (IT) services North and Latin America, India, rest of Asia, and Europe.

Genpact Limited’s sales growth this year is expected to be 7.6% and 9.7% for next year.

Year-on-year quarterly revenue growth grew by 9.8%, now sitting on 3.82B for the twelve trailing months.

Volume

Today’s last reported volume for Genpact Limited is 772913 which is 5.62% below its average volume of 818985.

Genpact Limited’s sales growth for the next quarter is 9.8%. The company’s growth estimates for the current quarter and the next is a negative 0% and 13.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.25%.

Volatility

Genpact Limited’s last day, last week, and last month’s current volatility was 2.14%, 1.49%, and 0.90%, respectively.

Genpact Limited’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.02% (day), 1.71% (last week), and 1.37% (last month), respectively.

Genpact Limited’s Stock Yearly Top and Bottom Value

Genpact Limited’s stock is valued at $49.97 at 01:22 EST, below its 52-week high of $52.75 and way above its 52-week low of $33.91.

Genpact Limited’s Moving Average

Genpact Limited’s worth is below its 50-day moving average of $51.04 and higher than its 200-day moving average of $46.41.

LEAVE A REPLY

Please enter your comment!
Please enter your name here